Drug intelligence / Profile preview

ITI-9001

Development stage: Phase 1
Lead developer: Immunomic Therapeutics
Modality: Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, mRNA Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics

Overview

ITI-9001 is an investigational mRNA-based therapeutic vaccine being developed by Immunomic Therapeutics for the treatment of peanut hypersensitivity (peanut allergy). It is designed to induce immune tolerance or modulate the immune response to peanut allergens, potentially reducing allergic reactions in affected individuals. The drug leverages RNA vaccine technology and is currently in preclinical development. Immunomic Therapeutics has also referenced ITI-9001 as an RNA vaccine candidate for Japanese Red Cedar Allergy, suggesting a broader platform application targeting various allergies[2][3].

Beyond the preview

Go deeper on ITI-9001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ITI-9001.

Explore the full profile